New data from Phase 3 studies provide additional evidence supporting treatment effect for oral BG-12 (dimethyl fumarate) in multiple sclerosis Biogen Idec, 12 Oct 2012 Accessed on 16 Oct 2012 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1744697. CommentRecommendBookmarkWatch